F.P.O

š


P٢ Pharmacode supplied by IPR

60009


ESTORE B ΓΙΟ LISINOPRIL/HYDROCHLOROTHIAZIDE

USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is delected, ZESTORETIC should be discontinued as soon as possible. See WARNINGS, Pregnancy, Lisinopril, Feta/Weonatal Morbidity and Mortality.

DESCRIPTION ZESTORETIC® (Lisinopril and Hydrochlorothiazide) combines an angiotensin converting enzyme inhibitor, lisinopril, and a diuretic, hydrochlorothiazide. Lisinopril, a synthetic peptide derivative, is an oral long-acting angiotensin converting enzyme inhibitor. It is chemically described as (S)-1-{/W2(1-carboxy-3-phenylpropyi)-1-ysyi]-1-proline dihydrate. Its empirical formula is C₂₁H₃₁N₃O₅ - 2H₂O and its structural formula is:



Lisinopril is a white to off-white, crystalline powder, with a molecular weight of 441.53. It is soluble in water, sparingly soluble in methanol, and practically insoluble in ethanol. Hydrochlorothiazide is 6-chloro-3.4-dihydro-2H-1,2.4-benzothiadi-azine-7-sulfonamide 1,1-dioxide. Its empirical formula is C₇H₈CIN₃04₅2 and its structural formula is:



Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution. ZESTORETIC is available for oral use in three tablet combinations of lisinopril and 12.5 mg hydrochlorothiazide; ZESTORETIC 10-125 containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide; ZESTORETIC 20-125, containing 20 mg lisinopril and 12.5 mg hydrochlorothiazide; and, ZESTORETIC 20-25 containing 20 mg lisinopril and 25 mg hydrochloro-thiazide. 10-12.5 Tablets - calcium phosphate, magnesium stearate, mannitol, red ferric oxide, starch, yellow feric oxide. 20-12.5 Tablets - calcium phosphate, magnesium stearate, mannitol, stard.

20-12.7 ratios calcium phosphate, magnesium stearate, mannitol, red ferric oxide, starch, yellow ferric oxide.

20-20 Jables - Calum priosphate, magnesium stearale, mannuo, red ferric oxide, star-ch. yellow ferric oxide. **CLINICAL PHARMACDLOGY Lisinopri and Hydrochlorothiazide** As a result of its diuretic effects, hydrochlorothiazide increases plasma renin activity, increases aldosterone secretion, and decreases serum potassium. Administration of lisinopril blocks the renin-angiotensin aldos-terone axis and tends to reverse the potassium loss associated with the diuretic. In clinical studies, the extent of blood pressure reduction seen with the combination of lisinopril and hydrochlorothiazide was approximately additive. The ZESTORETIC 10-12.5 combination worked equally well in black and white patients. The ZESTORETIC 20-12.5 and ZESTORETIC 20-25 combinations appeared somewhat less effective in black patients, but relatively few black patients were studied. In most patients, the anthy-pertensive effect of ZESTORETIC 10-25. and ZESTORETIC 20-25 combinations appeared to zestore the relative or the latter comb-intation may be controlled comparison, the mean antihypertensive effects of ZESTORETIC 20-12.5 and ZESTORETIC 20-25. Gee DOSAGE AND ADMINISTRATION.) Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on the bioavaliability of either drug. The combination table is bloequivalent to concomitant administration of the separate entities. **Lisinopril**

or no effect on the bioavailability of either drug. The combination tablet is bioequivalent to concomitant administration of the separate entities. Lisinopril Mechanism of Action: Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates addosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II which leads to decreased vasoressor adtivity and to decreased addosterone secretion. The latter decrease may result in a small increase of serum potassium. Removal of angiotents II lengative decreades (addosterone secretion. The latter decrease may result in a small increase of serum potassium. Removal of angiotents II lengative decreades (addosterone secretion. The latter decrease may result in a small increase of serum potassium. Removal of angiotents hal increases greater than 0.5 mEq/L and approximately for percent phatents had increases greater than 0.5 mEq/L and paproximately of percent of patients had increases greater than 0.5 mEq/L and approximately on pathers had increases greater than 0.5 mEq/L and paproximately suppression of the reinarians to be devicated. White the mechanism through which lisinopril lows a thizide diuretic solved essentially no change in serum potassium. (See PHECAUTIONS.) ACE is identical to kininase, an enzyme that degrades bardykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, and approximately also uptivension of the reinariang to bedivated ad. White the mechanism through which lisinopril lows this blood pressure is believed to be primarily suppression of the rein-angiotensin-addosterone system, lisinopril is antihypertensive even in patients with low-rein hyper-tension. Atthough lisinopril was antihypertensive potidation) had a smaller average response to lisinopril monotherapy than nonblack telinent.

nypertensive patients (usually a low-remin inypertensive population) had a smaller average response to lisinopril monotherapy than nonblack patients. **Pharmacokinetics and Metabolism:** Following oral administration of lisinopril monotherapy than nonblack serum concentrations excite a prolonget terminal phase probably represents saturable binding to ACE and is prolonget terminal phase. Probably represents saturable binding to ACE and is not proportional to dose. Lisinopril dose not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of absorption of lisinopril asportimely 25 percent, with large intersubject variability (6%-60%) at all doses tested (5-80 mg). Lisinopril doses not undergo metabolism and is excreted unchanged entirely in the urine. Based on urinary recovery, the mean extent of accumulation of 12 through the presence of food in the gastrointestinal tact. Upon multiple dosing, lisinopril exhibits an effective half-life of accumulation of 12 more. Impaired renal function decreases elimination of lisinopril, which is excreted principally through the kidneys, but this decrease becomes clinically important only when the giomerular filtration rate is below 30 mL/min. Above this glomerular filtration rate, the elimination half-life is tatina steady state is prolonged. Older patients, is under the plasma concerntration time curve (AUC) than younger patients (see DOSAGE AND ADMINSTRATION). In a multiple dose pharmacokinetic study in elderly rough the proverse pade patients (see DOSAGE AND ADMINSTRATION). In a multiple dose pharmacokinetic study in elderly following administration of 14C lisinopril. By whole body autoradiography, radioactivity was found in the placemat lollowing administration of 14C lisinopril. By whole body autoradiography, radioactivity was found in the placemat following administration rates with hypertension results in a reduction of supine and standing blood for the fusion. By whole body autoradiography, radioactivity was foun

tivity was found in the placenta following administration of labeled drug to pregnant rats, but none was found in the fetuses. **Pharmacodynamics:** Administration of lisinopril to patients with hypertension results in a reduction of supine and standing blood pressure to about the same extent with no compensatory tachycardia. Symptomatic postural hypotension is usually not observed although it can occur and should be anticipated in volume and/or salt-depleted patients. (See WARNINGS.) In most patients studied, onset of antihypertensive activity was seen at one hour after oral administration of an individual dose of lisinopril, with peak reduction of blood pressure achieved by six hours. At recommended single daily doses, antihypertensive effects have been maintained for at least 24 hours, after dosing, although the effect at 24 hours was substantially smaller than the effect six hours after dosing. The anthypertensive effects of lisinopril have continued during long-term therapy. Abrugt withdrawal of lisinopril have continued during long-term therapy. Abrugt withdrawal of isinopril have to been associated with a rapid increase in blood pressure. In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral afterial resistance with little or no change in cardiac output and in heart rate. In a study in nine hypertensive aritens, following administration of lisinopril, there was an increase in mean renal blood flow that was not significant. Data form several small studies are inconsistent with respect to the effect of lisinopril on glomerular filtration rate in hypertensive patients with normal renal function, but suggest that changes, if any, are not farge. In patients with renovascular hypertension lisinopril has been shown to be well tolerated and effective in controlling blood pressure. (See PECAUTIONS.) **Hydrochrothizzide**

PHECAUTIONS.) Hydrochlorothiazide The mechanism of the antihypertensive effect of thiazides is unknown. Thiazides do not usually affect normal blood pressure. Hydrochlorothiazide is a diuretic and antihypertensive. It affects the distal renal tubular mechanism of electrolyte reabsorption. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bloarbonate.

Increases Excited on soundin and companied by some loss of polassium and bicarbonate. After oral use diuresis may be accompanied by some loss of polassium and bicarbonate. After oral use diuresis begins within two hours, peaks in about four hours and lasts about 6 to 12 hours. Hydrochicorthinaizole is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the least 61 percent of the oral dose is eliminated unchanged within 24 hours. Hydrochicorthizide crosses the placental but not the blood-brain barrier. **INDICATIONS AND USAGE** ZESTORETIC: Is indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND DAMINISTRATION). In using ZESTORETIC, consideration should be given to the fact that an angiotensin-coverting enzyme inhibitor, captorin, has caused agranulo-cytosis, particularly in patients with renal impairment or collagen vascular on considering the use of ZESTORETIC, it should be noted that ACE inhibitors have been associated with a higher rate of angiodema in black than in nonblack patients (see WARNINGS, Lisinopri). **CONTRANDICATONS**

CONTRAINDCATIONS ZESTORETIC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Because of the hydrochloroth-iadde component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

With intercluinty of the sufformative dense because on the hydrochinobul-izatice component, this products is contraindicated in patients with anutra or hypersensitivity to other sufformative derived drugs. WARNINGS Lisinopril Anaphytactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polyopetides, including endogenous bradykinin, patients receiving ACE inhibitors (including ZESTORETIC) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Anglicedema: Angloedema of the face, extremities, lips, fongue, glottis and/or largvin has been reported rarely in patients treated with anglotensin-converting enzyme inhibitors, including lisinopril. This may occur at any time during treatment. ACE inhibitors have been associated with a higher rate of angloedema in black than in nonblack patients. ZEOTRETIC should be provided until complete and sustained resolution of signs and symptoms has occurred. Even in those sustained esolution of signs and symptoms has occurred. Even in those to the angloedema: Angloedema as observation since treatment with antihistamines and corticosteroids may not be sufficient. Very rarely, fatalities have been peopried due to angloedema associated with largue defma or tongue edema. Patients with involvement of the tongue, glottis or largvin are likely to experience airway obstruction, especially those with a history of airway surgery. Mhere there is involvement of the tongue, glottis or largvin, likely to cause airway obstruction, subcutaneous eginephrine these patient airway should be promptly provided. (See ADVERSE REACTIONS.). Instents Invaloedema: Intestinal angloedema ashould be indicitor atory of hardy or without anglesed or wanting?; in some seeshere vormal. The angloedema was diagnosed by procedures including abdomial pain (with or vithout anglesed or wanting?; in some seeshere vorgen at history of angloedema unrelated to ACE inhibitors mereaning with hashistory of angloe

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also INDICATIONS AND USAGE and CONTRAINDICATIONS).

Anaphylactoid Reactions During Desensitization: Two patients under-going desensitizing treatment with hymenoplera venom while receiving ACE inhibitors sustained life-threatening anaphylactiod reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withhed, but they reappeared upon inadvertent rechallenge.

inhibitors sustained life-threatening anaphylactioid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge. **Anaphylactioid Reactions During Membrane Exposure:** Thiazide-containing combination products are not recommended in patients with severe renal dysfunction. Sudden and potentially life-threatening anaphylactoid reactions have been reported in some patients dialyzed with high-fuer wembranes (e.g.AMS99²⁰) and treated concomisantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and agressive therapy for anaphylactoid reactions be initiade. Symptoms have been relieved by antihistamines in these situations. In these patients, considerations have been reported in some patients dialysis membrane or a different class of antihypertensive agent. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein aphresis with deviatra sultate absorption. **Hypotension and Related Effects:** Excessive hypotension was rarely seen in uncomplicated hypertensive rapitients but is a possible consequence of lisinopril use in salt/volume-depleted persons such as those treated vigorously with diuretics or patients on dialysis. (See PRECAUTIONS, Drug Interactions, ADVERSE REACTIONS.) Syncope has been reported in 0.8 percent fo patients receiving ZESTORETIC. In patients with hypertension receiving lisinopril alone, the incidence of syncope was 0.1 percent. The overall incidence of syncope may be reduced by proper titration, ADVERSE REACTIONS.) Due to these patients, but therapy should be started under very close medical supervision. Such patients, but be started under very close medical supervision. Such patients hould be started under very close medical supervision. Such patients hould be started under very two weeks of treatment and whenever the does of lisiopril and/or diurcitic is increased. Similar considerations apply to patients with ischemic heart or cerebr

Increased after volume expansion. Leukopenia/Neutropenia/Agranulocytosis: Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of lisinopril are insufficient to show that lisinopril does not cause agranulocytosis at similar rates. Marketing experience has revealed rare cases of leukopenia/neutropenia and bone marrow depression in which a causal relationship to lisinopril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered. Hepatic Failure: Rarely, ACE inhibitors have been associated with a syndrome that stark with cholestatic jaundice or hepatitis and progresses to fulninant hepatic necrosis and (sometimes) death. The mechanism of dis syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discon-tinue the ACE inhibitor and receive appropriate medical follow-up. Pregnancy

time the ACE inhibitor and receive appropriate medical follow-up. Pregnancy Lisinopril and Hydrochlorothiazide: Teratogonicity studies were conducted in mice and rats with up to 90 mg/kg/day of lisinopril (56 times the maximum recommended human does) in combination with 10 mg/kg/day of hydrochlorothiazide (2.5 times the maximum recom-mended human does). Maternal or fetotoxic effects were not seen in mice with the combination. In rats decreased maternal weight gain and decreased fetal weight occurred down to 370 mg/kg/day (the lowest dose tested). Associated with the decreased fetal weight was a delay in fetal sosification. The decreased fetal weight metal dosignication were not seen in saline-supplemented animals given 80/10 mg/kg/day. When used in pregnancy diedected, ZSE/ONETIC should be discontinued as soon as possible. (See Lisinopril, fetal/Neonatal Morbidity and Mortality below.) Lisinopril

inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ZSTORFIC should be discontinued as soon as possible. (See Lisinopril, Fetal/Neonatal Morbidity and Mortality below.)
 Lisinopril
 Tetal/Neonatal Morbidity and Mortality: ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the word literature. When pregnancy is detected, ACE inhibitor therapy should be discontinued as soon as possible.
 The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anura, reversible or irreversible renal faulture, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal mbo contractures, craniofacial deformation, and hypoplasitc lung development. Prematurity, intrautering growth retardation, and patern ductus arterious have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure that has been limited to the first timester. Mothers Works embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become gregnant, physicians should make every effort to discontinue the use of ZETORFIC should be discontinue to ACE inhibitor will be formed. In these setus (ZETORFIC should be discontinue to the setus is is considered lifesaving for the mother. Contraction stress testing (CST), or toinghysical profiling (PPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be assustand reversible reversion of disysis and be entormed to assess the opportain. Should be appr

Recommendee numera uses. Hydrochlorothinazide Teratogenic Effects: Reproduction studies in the rabbit, the mouse and the rat at doses up to 100 mg/kg/day (50 times the human dose) showed ne evidence of external abnormalities of the fetus due to hydrochlorothiazide. Hydrochlorothiazide given in a two-litter study in rats at doses of 4.56 mg/kg/day (approximately 1.2 times the usual daily human dose) did not impair fertility or produce birth abnormalities in the offspring. Thiazides cross the placental barrier and appear in cord blood. Monterstenesis Effect: These may include fetal or negonatal jaundice.

Organity, milazides cross the placental barrier and appear in cord blood. Nonteratogenic Effects: These may include fetal or neonatal jaundice thrombocytopenia, and possibly other adverse reactions have occurred in the adult.

In the adult. Hydrochlorothiazide Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte blackmene may precipitate hepatic coma. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with thiazides. (See PRECAUTIONS)

RECAUTIO

Cough: Presumably due to the inhibition of the degradation of endogenous bradyklinin, persistent nonproductive cough has been reported with all ACE inhibitor-induced cough should be considered in the differential diagnosis of cough. th

SurgeryAnextEstaiz: In patients undergoing major surgery or during anesthesia with agents that produce hypotension, lisinopril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

be corrected by volume expansion. Hydrochlorothiazide Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed a appropriate intervals. All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance: namely, hyponatremia, hypo-chloremic atkaolsis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting accessively or receiving parenteral fluids. Warving signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thrist, weakness, leitargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tactycardia, and gastrointestinal disturbances such as nausea and vomiting.

ay develop, especially with brisk diuresis, when severe t, or after prolonged therapy. Hypokalemia m rhosis is preser

(CONTINUED ON REVERSE SIDE)

<text><text><text><text><text><text><text><text><text><text>

physician. Symptomatic Hypotension: Patients should be cautioned to report lightheadedness especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure; patients should be adviced to consult with their physician. Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

Leukopenia/Neutropenia: Patients should be told to report promptly any indication of infection (eg, sore throat, fever) which may be a sign of leukopenia/neutropenia.

Indication or infection (eg), sore infract, revery which may be a sign or ideukopenia/neutropenia. **Pregnancy:** Female patients of childbearing age should be told about the consequences of second- and third-timester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACF-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible. **NOTE:** As with many other drugs, certain advice to patients being treated with ZESTORETIC is warranted. This information is intended to aid in the possible adverse or intended effects.

Drug Interactions

Listingenti Hypotension - Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinoprii. The possibility of hypotensive effects with lisinoprii can be minimized by either discontinuing the diuretic or increasing the sait intake prior to initiation of treatment with lisinoprii. If it is necessary to continue the diuretic, initiate therapy with lisinoprii at and provide close medical supervision after the initial dose for at elast two hours and until blood pressure has stabilized for at least an additional hour; Gee WARNINGS, and DOSAGE AND ADMINISTRATION.) When a diuretic is added to the therapy of a patient receiving lisinoprii, an Additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION.) Mon-stercialal Anti-inflammatory Anents: In some patients with

ADMINISTRATION.) Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a turther deterioration of renal function. These effects are usually reversible. In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of lisionpril alone were compared to lisinopril given concomitantly with indomethacin, the use of indomethacin was associated with a reduced effect, although the difference between the two regimens was not significant.

What a tockdownet, a landough the Uniteriorie Derivent her two regimens was not significant. Other Agents: Lisnopril has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. No meaningful clinically important pharmacokinetic interac-tions occurred when lisnopril was used concomitantly with propranolol, digoxin, or hydrochlorothiazide. The presence of food in the stomach does not alter the bioaxiability of lisnopril. Agents Increasing Serum Potassium: Lisnopril attenuates potassium loss caused by thiazide-type diuretics. Use of lisnopril with potassium -sparing diuretics (eg. spironolactone, <u>epiteronne</u>, triamterene, or amilorinde), potassium supplements, or potassium. Decause of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potasium.

Libium: Libium toxicity has been reported in patients receiving libium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. Libium toxicity was usually reversible upon discontinuation of libium and the ACE inhibitor. It is recommended that serum libium levels be monitored frequently if lisinopril is administered concomitantly with libium.

Hydrochlorothiazide When administered concurrently the following drugs may interact with

When administered concurrently the following drugs may interact which thazide diureits. Alcohol, barbiturates, or narcotics - potentiation of orthostatic hypotension may occur. Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs - additive effect or potentiation. Cholestyramine and colestipol resins - Absorption of hydrochloro-thizaide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochloro-thizaide ain required in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochloro-thizaide ain dreue is absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosterolist, ACTH - intensified electrolyte depletion, particularly hypokalemia.

85 and +3 percent, respectively. Corricosteroids, ACTH - intensified electrolyte depletion, particularly hypokalemia. Pressor amines (eg, norepinephrine) - possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle relaxants, nondepolarizing (eg, tubocurarine) -possible increased responsiveness to the muscle relaxant. Lithium - should not generally be given with duretics. Duretic agents reduce the renal clearance of ithium nard add a high risk of ithium toxicity. Non-Steroidal Anti-inflammatory Drugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the duretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide duretics. Therefore, when ESTORETIC dot 263TORETIC is obtained. Carcinogenesis, Mutagenesis, Impairment of Fertility

concomtantly, the patient should be observed closely to determine if the desired deter of ZESTORETIC is obtained. Carcinogenesis, Mutagenesis, Impairment of Fertility Lisinopril and Hydrochlorothiazide: Lisinopril in combination with hydrochlorothazide was not mutagenic in a microbal mutagen test using Salmonella typhimurum (Ames test) or *Escherichia* coli with or without metabolic activation or in a forward mutation assay using Chinese hamster lung cells. Lisinopril and hydrochlorothiazide did not produce DNA single strand bracks in an *in vitro* alkanice elution at the patocyte assay. In addition, it did not produce increases in chromosomal aberrations in an *in vitro* test in Chinese hamster ovary cells or in an *in vivo* study in mouse bone marrow. Lisinopril: There was no evidence of a tumorigenic effect when lisinopril was administered for 105 weeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times" the maximum daliy human does, based on body weight and body surface area, respectively). There was no evidence of carcinogenicity when lisinopril was administered for 92 weeks to imale him car doses up to 135 mg/kg/day (about 84 times" the maximum thuran dose based on body surface area in mice. "Calculations assume a human weight of 50 kn and human hordy surface un 135 mg/adda بر المراجب ا مراجب المراجب المر مراجب المراجب المراجع مراجب المراجب المراجب المراجب المراجب ال

The view of 16.2m². Lisinopril was not mutagenic in the Ames microbial mutagen test with or without metabolic activation. It was also negative in a forward mutation assay using Chinese hamster lung cells. Lisionopril did not produce single strand DNA breaks in an *in vitro* alkaline elution rat hepatocyte assay. In didition, lisionopril did not produce increases in chromosomal aberrations in an *in vitro* test in Chinese hamster ovary cells or in an *in vivo* study in mouse bone marrow. There were no adverse effects on reproductive performance in male and female rats treated with up to 300 mg/kg/day of lisinopril. This dose is 188 times and 30 times the maximum daily human dose based on mg/kg and mg/m², respectively. Hydrochlorrathiazite: Two unactivity and the start of th

Pregnancy Pregnancy Categories C (first trimester) and D (second and third trimesters). See WARNINGS, Pregnancy, Lisinopril, Fetal/Neonatal Morbidity and Mortality.

Morbidity and Mortality. **Nursing Mothers** It is not known whether lisinopril is excreted in human milk. However, milk of lactating rats contains radioactivity following administration of ¹⁴C lisinopril. In another study, lisionpril was present in rat milk at levels similar to plasma levels in the dams. Thiazides do appear in human milk. Because of the potential for serious adverse reactions in nursing infants from ACE inhibitors and hydrochiorothiazide, a decision should be made whether to discontinue nursing and/or discontinue ZESTORETIC, taking into account the importance of the drug to the mother.

Pediatric Use Safety and effect eness in pediatric patients have not been establis

Safety and effectiveness in pediatric patients have not been established. Generatire Use Clinical studies of ZESTORETIC did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, are should be taken in dose selection. Frauduction of the hypertensive patient should always include assessment of renal function. **AUVERSE REACTIONS**

ADVERSE REACTIONS

AVERSE REACTIONS ZESTORETIC has been evaluated for safety in 930 patients including 100 patients treated for 50 weeks or more. In clinical trials with ZESTORETIC no adverse experiences paculiar to this combination of ung have been observed. Adverse experiences that have occurred have been limited to those that have been previously reported with lisinopri or hydrochiorthizaide. The most frequent clinical adverse experiences in controlled trials (including open label extensions) with any combination of lisinoprii and hydrochiorthizaide were: dizines (7.3%), headache (52%), cough (3.9%), fatigue (3.7%) and orthostatic effects (3.2%) all of which were experiences were mild and transient in nature, but see WARNINGS Discontinuation of therapy due to adverse effects was required in 4.4% of patients principally because of dizziness, cough, fatigue and muscle camps. Adverse experiences occurring in greater than one percent of patients treated with lisinopril plus hydrochlorothizaide in controlled clinical trials are shown below. Percent of Patients in Controlled Studies

Percent of	f Patients in Controlled S Lisinopril and Hydrochlorothiazide (n=930) Incidence (discontinuation)		Placebo (n=207) Incidence	
Dizziness Headache Cough Fatigue Orthostatic Effects Diarrhea Nausea Upper Respiratory Infection Muscle Cramps Asthenia Paresthesia Hypotension Vomiting Dyspepsia Rash Imootence	7.5 5.2 3.9 3.7 2.5 2.2 2.2 2.0 1.8 1.5 1.4 1.4 1.3 1.2	(0.8) (0.3) (0.6) (0.4) (0.1) (0.2) (0.1) (0.2) (0.1) (0.2) (0.4) (0.2) (0.1) (0.3) (0.1) (0.3) (0.1) (0.3)	$\begin{array}{c} 1.9\\ 1.9\\ 1.0\\ 1.0\\ 2.4\\ 2.4\\ 0.0\\ 0.5\\ 1.0\\ 0.5\\ 0.5\\ 0.5\\ 0.0\\ 0.5\\ 0.5$	

Clinical adverse experiences occurring in 0.3% to 1.0% of patients in controlled trials and rarer, serious, possibly drug-related events reported in marketing experience are listed below: **Body as a Whole**: Chest pain, abdominal pain, syncope, chest discomfort, fever, trauma, virus infection. **Cardiovascular**: Palpitation, constipation, hearburn. **Musculoskeleta**: Back pain, shoulder pain, kack strain, myalqia, foot pain. **Nervoux/Psychiatric**: Decreased libido, vertigo. depression. somolence. **Respiratory**: Common cold, nasa congestion, nituenza, bronchitis, pharyngeal pain, dyspnea, pulmonary congestion, chronic sinusitis, allergic rhinitis, pharyngeal **Senses**: Blurred vision, tinnitus, otalgia. **Urogenita**: Urinary tract infection. **Angioedema**: Angloedema of the face, extremities, lips, tongue, glottis and/or larynk tas been reported rarely. (See WARNINGS.) In rare cases, intestinal angioedema has been reported in post marketing experience. **Hypotension**: In clinical trials, adverse effects relating to hypotension.

Hypotension: In clinical trials, adverse effects relating to hypotension occurred as follows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects (3.2%). In addition syncope occurred in 0.8% of patients. (See WARNINGS.) Cough: See PRECAUTIONS - Cough.

Clinical Laboratory Test Findings Serum Electrolytes: (See PRECAUTIONS.) Creatinine, Blood Urea Nitrogen: Minor reversible increases in blood urea nitrogen and serum creatinine were observed in patients with essential hypertension treated with ZESTORETIC. More marked increases have also been reported and were more likely to occur in patients with renal artery stenosis. (See PRECAUTIONS.)

Serum Uric Acid, Glucose, Magnesia Calcium: (See PRECAUTIONS). um, Cholesterol, Triglycerid

Catching: [See PreCADIONS]. Hemoglobin and Hematcerit: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.5 g/% and 1.5 vol%, respectively) occurred frequently in hypertensive patients treated with ZESTORETIC but were rarely of clinical importance unless another cause of anemia coexisted. In clinical trials, 0.4% of patients discontinued therapy due to anemia. ernía e to a

Liver Function Tests: Rarely, elevations of liver enzymes and/or serum bilirubin have occurred. (See WARNINGS, Hepatic Failure.) Other adverse reactions that have been reported with the individual components are listed below:

bilinubin have occurred. (See WARNINGS, Hepatic Faiure.) Other adverse reactions that have been reported with the individual components are listed below: Lisinopril - In clinical trials adverse reactions which occurred with lisinopril vere also seen with ZESTORETIC. In addition, and since lisinopril has been marketed, the following adverse reactions which occurred with lisinopril vere also seen with ZESTORETIC. In addition, and since lisinopril has been marketed, the following adverse reactions have been reported with lisinopril and should be considered potential adverse reactions for ZESTORETIC. Body as a Whole: Anaphylactoid reactions (see Cardiovascular Cardiac arrey, myocardial infaction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension), pulmonary embolism and infarction, worsening of heart failure, arrhythmias (including tachycardia, and premature ventricular contractions), angina pectoris, transient ischemic attacks, paroxysma nocturnal dysprea, decreased blood pressure, peripheral edema, vasculitis, Digestive: Pancreatitis, hepatitis (hepatocellular o cholestatic jaunotice) (see WARNINGS, Hepatic Failure), gastritis, anorexia, flatulence, increased salivation; Endocrine: Diabetes melitus; Hematologic: Rarc cases of bone marcow depression, hemolytic anemia, leukopenia/heutropenia, and thrombocytopenia have been reported in which a causal relationship to lisinopril can not be excluded; Metabolic: Gout, weight toss, dehydration, fluid overload, weight gain, intrability, Respiratory Malignant Lung neoplasms, hemolysis, pulmoarry edema, pulmonary infiltrates, bronchopasm, asthma, orthora, alopecia, herpes zoster, photosenstor, laste alteration, spinare, line seeser solutionship has no lopalesms, hemolysis, pulmonary edema, pulmonary infiltrates, bronchopasm, asthma, reatabilitus; Hamagia, ekey asses of other seeser solutes, solusionship, Spinar, alito, neuemonia, esolito, puenemonitis, subecrin, breat, and o

Feta/Neonatal Morbidity and Mortality See WARNINGS - Pregnancy, Lisinopril, Feta/Neonatal Morbidity and ortality. Mo

Mortality. Hydrochlorolhiazide - Body as a Whole: Weakness; Digestive: Anorexia, gastric irritation, cramping, jaundice (intrahepatic cholestatic jaundice) (See WARNINGS, Hepatic Failure), pancreative sioladenitis, constipation; Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, hemolylic anemia; Musculoskeltati: Muscle spasm; Nervous System/Fzychlatric: Restlessness; Renal: Renal Bilure, renal dysfunction, interstitial nephnitis (see WARNINGS); Skin: Erythema multitorme including Stevens-Johnson syndrome, extoliative dermatitis including toxic epidermal incorv)sis, alopecia; Special Senses; Xanthopsia; Hypersensitivity; Purpura, photosensultis), respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions. OVERDOSAE

VERDOSACE No specific information is available on the treatment of overdosage wit ZESTORFIC. Treatment is symptomatic and supportive. Therapy wit ZESTORFIC should be discontinued and the patient observed closely Suggested measures include induction of emesis and/or gastric lavage, an correction of dehydration, electrolyte imbalance and hypotension by estat lished procedures. , d

lished procedures. Lisinopril: Following a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution. Lisinopril can be removed by hemodialysis (see WARNINGS, Anaphylactioi Reaction During Membrane Exposure). Hydrochiorohiazide: Oral administration of a single oral dose of 10 g/kg to mice and rats was not lethal. The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochioremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias. DOSAGE AND ADMINISTRATION

duress: If digitals has also been administered, hypokalemia may accentuate cardiac arrhythmias. DOSAGE AND ADMINISTRATION Lisinopril monotherapy is an effective treatment of hypertension in one-daily doses of 10-80 mg, while hydrochlorothiazide monotherapy is effective in doses of 12.5 - 50 mg per day. In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10-80 mg and hydrochlorothiazide doses of 6.25-50 mg, the antihypertensive response rates generally increased with increasing dose of either component. The side effects (see WANNINGS) of lisinopril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent or dose-dependent side effects, but addition of lisinopril and hydrochlorothiazide may be associated with either or both dose-dependent side effects, but additions to itsinopril combination therapy only after a patient has failed to achieve the desired effect with monotherapy. Dose Tirtation Guided by Clinical Effect: A patient whose blood

begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.
Dose Titration Guided by Clinical Effect: A patient whose blood pressure is not adequately controlled with either lisinopril or hydrochirorthizaide monotherapy may be switched to lisinopril/HCTZ 10/12.5 or lisinopril/HCTZ 10/12.5

Replacement Therapy: The combination may be substituted for the titrated individual components.

titrated individual components. Use in Renal Impairment: Regimens of therapy with lisinopril/HCTZ need not take account of renal function as long as the patient's creatinue (cearance is -30 mL/min/1 / mC/ serum creatinine roughly = 3 mg/dL or 265 µmo/L). In patients with more severe renal impairment, long diuretics are preferred to thiazides, so lisinopril/HCTZ is not recommended (see WARNINGS, Anaphylactoid Reactions During Membrane Exposure).

WARNINGS, Anaphylactoid Reactions During Membrane Exposure). HOW SUPPLIED ZESTORETIC 10-12.5 Tablets (NDC 0310-0141) Peach, round, biconvex, uncoated tablets identified with "141" debossed on one side and "ZESTORETIC 20-12.5 Tablets (NDC 0310-0142) White, round, biconvex, uncoated tablets identified with "142" debossed on one side and "ZESTORETIC 20-12.5 Tablets (NDC 0310-0142) White, round, biconvex, uncoated tablets identified with "142" debossed on one side and "ZESTORETIC 20-25 Tablets (NDC 0310-0142) White, round, biconvex, uncoated tablets identified with "145" debossed on one side and "ZESTORETIC" on the other side are supplied in bottles of 100 tablets. Store at controlled room temperature, 20-25°C (68-77°F) [see USP]. Protect from excessive light and humidity.

*AN69 is a registered trademark of Hospal Ltd. ZESTORETIC is a trademark of the AstraZeneca group of companies. © AstraZeneca 2002, 2003, 2005

Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850 By: IPR Pharmaceuticals, Inc., Carolina, PR 00984

660009 Rev 12/05

AstraZeneca

